Personalis (PSNL) Aktievy
Personalis, Inc. utvecklar, marknadsför och säljer avancerade cancergenomiska tester och tjänster i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
PSNL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Personalis, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$14.50 |
| 52 veckors högsta | US$16.39 |
| 52 veckors lägsta | US$4.42 |
| Beta | 2.28 |
| 1 månads förändring | 3.06% |
| 3 månaders förändring | 140.07% |
| 1 års förändring | 222.22% |
| 3 års förändring | 667.20% |
| 5 års förändring | -18.45% |
| Förändring sedan börsintroduktionen | -49.10% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 07
PSNL: Tempus Deal And MRD Franchise Will Reprice Future Risk Reward
Analysts have lifted their fair value estimate for Personalis, with the price target moving from $13.00 to $16.25 as they factor in the agreed all stock acquisition by Tempus AI at $16.25 per share and the perceived fit of Personalis' MRD franchise within Tempus AI's precision oncology portfolio. Analyst Commentary Recent commentary on Personalis following the Tempus AI all stock acquisition agreement has leaned constructive, with several bullish analysts highlighting both the agreed transaction value of $16.25 per share and the fit of Personalis' MRD assets within a larger precision oncology platform.
Uppdatering av berättelse • Jul 24
PSNL: Pending Tempus Acquisition And MRD Milestones Will Support Future Upside
Analysts lifted their price target for Personalis from $10.86 to $13.88, citing the agreed $16.25 per share all-stock acquisition by Tempus AI and the view that the deal terms now anchor valuation expectations. Analyst Commentary Recent research on Personalis clusters around the Tempus AI all stock acquisition, with analysts focusing on how the agreed US$16.25 per share deal shapes valuation, execution risk, and future growth ambitions for the combined company.Seeking Alpha • Jul 21
Personalis: Tempus Bought The Best Part Of The Story
Summary Personalis reached a commercial inflection with accelerating clinical adoption, expanding Medicare reimbursement, and its differentiated MRD platform gaining traction. The Tempus AI all-stock acquisition at a modest 6% premium shifts PSNL from a standalone growth story to a derivative of TEM's share price. Despite strong operational momentum, PSNL shareholders now face capped upside and opportunity cost, as future value accrues to Tempus post-acquisition. I assign PSNL a Sell rating not due to business weakness, but because the investment thesis is now tied to waiting for Tempus shares. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Aug 07
PSNL: Tempus Deal And MRD Franchise Will Reprice Future Risk Reward
Analysts have lifted their fair value estimate for Personalis, with the price target moving from $13.00 to $16.25 as they factor in the agreed all stock acquisition by Tempus AI at $16.25 per share and the perceived fit of Personalis' MRD franchise within Tempus AI's precision oncology portfolio. Analyst Commentary Recent commentary on Personalis following the Tempus AI all stock acquisition agreement has leaned constructive, with several bullish analysts highlighting both the agreed transaction value of $16.25 per share and the fit of Personalis' MRD assets within a larger precision oncology platform.Uppdatering av berättelse • Jul 24
PSNL: Pending Tempus Acquisition And MRD Milestones Will Support Future Upside
Analysts lifted their price target for Personalis from $10.86 to $13.88, citing the agreed $16.25 per share all-stock acquisition by Tempus AI and the view that the deal terms now anchor valuation expectations. Analyst Commentary Recent research on Personalis clusters around the Tempus AI all stock acquisition, with analysts focusing on how the agreed US$16.25 per share deal shapes valuation, execution risk, and future growth ambitions for the combined company.Seeking Alpha • Jul 21
Personalis: Tempus Bought The Best Part Of The Story
Summary Personalis reached a commercial inflection with accelerating clinical adoption, expanding Medicare reimbursement, and its differentiated MRD platform gaining traction. The Tempus AI all-stock acquisition at a modest 6% premium shifts PSNL from a standalone growth story to a derivative of TEM's share price. Despite strong operational momentum, PSNL shareholders now face capped upside and opportunity cost, as future value accrues to Tempus post-acquisition. I assign PSNL a Sell rating not due to business weakness, but because the investment thesis is now tied to waiting for Tempus shares. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 10
PSNL: Ongoing Clinical Spending And Equity Offering Will Pressure Longer Term Upside
Analysts have increased the fair value estimate for Personalis from $9.00 to $10.00, citing updated models and a higher price target of $13.00 as they refine expectations ahead of upcoming earnings. Analyst Commentary Recent research updates on Personalis show a mix of optimism and caution as analysts adjust their models ahead of upcoming earnings.Uppdatering av berättelse • Jun 19
PSNL: Recent Coverage, Clinical Progress And Losses Will Shape Longer Term Upside
Analysts have reduced their price targets on Personalis stock by about $1 to $2, citing updated fair value estimates near $9.00, an adjusted discount rate, and refreshed assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary on Personalis Stock Recent research updates around Personalis reflect a more cautious tone, with price targets trimmed by about $1 to $2 as bearish analysts reassess valuation and execution risks.Analysartikel • Jun 16
Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data
Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...Uppdatering av berättelse • Jun 04
PSNL: Ultrasensitive MRD Evidence And Expanded Coverage Will Support Balanced Future Outlook
Analysts have trimmed their price targets on Personalis by $1 to $2, citing updated assumptions for discount rates, profit margins, and long term P/E expectations. These revisions result in a slightly lower overall valuation outlook.Uppdatering av berättelse • May 21
PSNL: Expanded Coverage And MRD Evidence Will Underpin Future Upside Potential
Analysts have nudged their average price target for Personalis lower by about $0.40. This reflects updated forecasts that factor in higher projected net losses and operating expenses in later years.Uppdatering av berättelse • May 01
PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential
Analysts have trimmed their price target on Personalis to $10 from $11, citing updated views on longer term operating expenses and expected net losses. These updates also feed into a slightly higher discount rate and future P/E assumptions in current models.Uppdatering av berättelse • Apr 16
PSNL: Higher Spending And 2026 Loss Will Set Up Longer Term Upside Potential
Analysts now converge around a $10 price target for Personalis, reflecting updated views that incorporate expectations for higher outer year operating expenses and a wider 2026 net loss. Analyst Commentary Recent research updates point to a more cautious tone around Personalis, particularly as analysts factor in guidance for higher operating expenses and a wider 2026 net loss.Uppdatering av berättelse • Apr 02
PSNL: Expanded Clinical Evidence And Coverage Will Support A Stronger Long Term Outlook
Analysts now center on a $10 price target for Personalis, citing updated loss expectations and higher longer term operating expense assumptions as key drivers of the shift from prior Street estimates. Analyst Commentary Bearish analysts are resetting expectations around Personalis, using the new $10 price target as a reference point for what they see as a more cautious risk and reward profile.Uppdatering av berättelse • Mar 19
PSNL: Medicare Coverage And MRD Data Will Reprice Future Risk Reward
Analysts have adjusted their view on Personalis, with price targets now ranging between $10 and $11 as they factor in updated expectations for future losses and operating expenses. Analyst Commentary Recent research updates on Personalis highlight a mix of cautious modeling changes and ongoing interest in the company’s longer term potential.Uppdatering av berättelse • Mar 05
PSNL: Medicare Coverage Will Support Future Risk Reward Repricing
Narrative Update on Personalis The analyst price target on Personalis has moved from $13 to $13.00 as analysts factor in updated assumptions around revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish analysts have adjusted their price targets on Personalis, with one recent move taking the target to $13.00.Uppdatering av berättelse • Feb 18
PSNL: Medicare Coverage And Refined Assumptions Will Support A Brighter Outlook
Analysts have increased their price target on Personalis by $1, citing updated views on fair value, slightly revised discount rate assumptions, and refreshed expectations for revenue growth, profit margin, and future P/E. Analyst Commentary Although the latest research includes a higher price target for Personalis, the tone around the stock remains measured.Uppdatering av berättelse • Feb 04
PSNL: Medicare Coverage For Cancer Surveillance Will Reshape Future Risk Reward Profile
Analysts have increased their fair value estimate for Personalis from US$9.00 to US$13.00, citing updated assumptions around revenue growth, profit margins, and future P/E. They have also incorporated recent Street research that reflected Medicare coverage news and refreshed price targets.Uppdatering av berättelse • Jan 21
PSNL: Medicare Coverage Will Shape Future Upside Despite Biopharma Headwinds
Narrative update on Personalis Analysts have lifted their blended price expectations for Personalis toward the US$9 to US$11 range, citing recent Medicare coverage for the NeXT Personal test and Q3 revenue that came in above guidance as key supports for the higher targets. Analyst Commentary Recent Street research on Personalis has focused on two main developments: Medicare coverage for the NeXT Personal test in breast cancer surveillance, and Q3 revenue that came in ahead of the guided range, internal estimates, and consensus.Analysartikel • Jan 17
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a really impressive month, gaining 28% after a shaky period...Uppdatering av berättelse • Jan 07
PSNL: Medicare Coverage And Biopharma Headwinds Will Shape A Balanced Outlook
Analysts lifted their projected fair value for Personalis, citing recent price target increases to $9 and $11, and pointing to Medicare coverage for the NeXT Personal test and reimbursement trends as key supports for their updated view. Analyst Commentary Recent research takes a mixed view on Personalis, with price targets being adjusted around specific catalysts such as Medicare coverage for NeXT Personal and reported Q3 revenue.Uppdatering av berättelse • Dec 23
PSNL: Medicare Coverage Will Drive Reimbursement Momentum And Support A Higher Share Price
Analysts have raised their price target on Personalis significantly, from about $5 to a range centered near $10 per share, citing stronger revenue growth expectations, improving profit margins, and increased confidence in long-term reimbursement trends. Analyst Commentary Recent target price revisions reflect a more constructive outlook on Personalis as reimbursement visibility improves and revenue trends modestly outperform prior expectations.Uppdatering av berättelse • Dec 09
PSNL: Medicare Reimbursement Will Drive Future Momentum Despite Biopharma Guidance Headwinds
Analysts have modestly raised their price target on Personalis, citing stronger-than-expected Q3 revenue and expanding reimbursement visibility. Their estimate of fair value has edged up from roughly $10.71 to $11.00 per share.Uppdatering av berättelse • Nov 24
PSNL: Medicare Coverage Will Support Momentum Despite Guidance Headwinds
Narrative Update on Personalis Analysts have raised their price target for Personalis from approximately $8.50 to $10.71 per share. They cite recent Medicare coverage for the NeXT Personal test and stronger-than-expected quarterly revenue as supporting factors for the upward revision.Uppdatering av berättelse • Nov 08
PSNL: Reimbursement Progress Will Drive Momentum Despite Guidance Reduction
Analysts have raised their fair value estimate for Personalis from $8.06 to $8.50 per share. They cite stronger revenue growth prospects and continued progress on reimbursement as key factors behind the upgrade.Analysartikel • Nov 07
Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50
Personalis, Inc. ( NASDAQ:PSNL ) just released its quarterly report and things are looking bullish. Revenues beat...Analysartikel • Oct 31
Personalis, Inc.'s (NASDAQ:PSNL) P/S Is Still On The Mark Following 46% Share Price Bounce
Despite an already strong run, Personalis, Inc. ( NASDAQ:PSNL ) shares have been powering on, with a gain of 46% in the...Uppdatering av berättelse • Oct 25
Clinical Testing Progress And Medicare Coverage Will Influence Share Momentum Ahead
Analysts have revised Personalis's price target downward from $8.00 to $6.00. They cite weaker than expected pharma order timing and softer profit projections, despite continued progress in clinical testing and Medicare coverage goals.Analysartikel • Sep 16
Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analysartikel • Sep 10
Is Personalis (NASDAQ:PSNL) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Aug 10
These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat
Today is shaping up negative for Personalis, Inc. ( NASDAQ:PSNL ) shareholders, with the analysts delivering a...Analysartikel • Aug 02
Personalis, Inc. (NASDAQ:PSNL) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
The Personalis, Inc. ( NASDAQ:PSNL ) share price has softened a substantial 28% over the previous 30 days, handing back...Analysartikel • May 06
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 37% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 37% in the...
Ny berättelse • Mar 30
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.Analysartikel • Mar 21
What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Personalis, Inc. ( NASDAQ:PSNL ) shareholders that were waiting for something to happen have been dealt a blow with a...Analysartikel • Mar 02
Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for Personalis, Inc. ( NASDAQ:PSNL ), who've watched their investment drop 12% to US$4.14 in the...Analysartikel • Feb 04
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 26% after a relatively good period...Analysartikel • Nov 19
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Personalis, Inc. ( NASDAQ:PSNL ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 28
The Proper Play On Personalis
Summary Today, we revisit the diagnostic concern of Personalis, Inc. The company recently expanded its partnership with Tempus AI and is seeing lower quarterly losses. The company has a solid balance sheet, strong analyst support, and is seeing revenue growth in a large and growing market. An updated analysis around Personalis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Sep 14
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Personalis, Inc. ( NASDAQ:PSNL ) shares have continued their recent momentum with a 28% gain in the last month alone...Analysartikel • Jul 25
A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Personalis, Inc. ( NASDAQ:PSNL ) shareholders have had their patience rewarded with a 131% share price jump in the last...Analysartikel • Apr 19
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 25% after a relatively good period...Analysartikel • Mar 02
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Personalis, Inc. ( NASDAQ:PSNL ) shareholders would be excited to see that the share price has had a great month...Aktieägarnas avkastning
| PSNL | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | 9.8% | 5.0% | 2.2% |
| 1Y | 222.2% | 27.6% | 20.9% |
Avkastning vs industri: PSNL översteg US Life Sciences branschen som gav 27.6 % under det senaste året.
Avkastning vs Marknaden: PSNL översteg US marknaden som gav 20.9 % under det senaste året.
Prisvolatilitet
| PSNL volatility | |
|---|---|
| PSNL Average Weekly Movement | 12.2% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: PSNL s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: PSNL s veckovolatilitet ( 12% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2011 | 260 | Chris Hall | www.personalis.com |
Personalis, Inc. utvecklar, marknadsför och säljer avancerade cancergenomiska tester och tjänster i USA och internationellt. Bolaget erbjuder NeXT Personal, ett tumörinformerat vätskebiopsi-test för detektion av minimal restsjukdom (MRD), terapisvar och återfallsövervakning i solida tumörcancerformer; och ImmunoID NeXT, en vävnadsbaserad tjänst som kombinerar sekvenseringsdata från hela exom och hela transkriptom med avancerad analys för att ge en flerdimensionell bild av tumören och tumörens mikromiljö från ett enda prov. Företaget tillhandahåller också NeXT Personal Dx, ett tumörinformerat vätskebiopsi-test för detektion av MRD, och NeXT Dx, ett tumörprofileringstest som används för att hjälpa till att välja behandling för en cancerpatient och identifiera potentiella kliniska prövningar för en patient.
Personalis, Inc. Sammanfattning av grunderna
| PSNL grundläggande statistik | |
|---|---|
| Börsvärde | US$1.51b |
| Vinst(TTM) | -US$107.18m |
| Intäkter(TTM) | US$69.67m |
22.2x
P/S-förhållande-14.4x
P/E-förhållandeÄr PSNL övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PSNL resultaträkning (TTM) | |
|---|---|
| Intäkter | US$69.67m |
| Kostnad för intäkter | US$60.83m |
| Bruttovinst | US$8.84m |
| Övriga kostnader | US$116.02m |
| Intäkter | -US$107.18m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -1.00 |
| Bruttomarginal | 12.69% |
| Nettovinstmarginal | -153.84% |
| Skuld/egenkapitalförhållande | 0.4% |
Hur har PSNL utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/10 16:20 |
| Aktiekurs vid dagens slut | 2026/08/10 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Personalis, Inc. bevakas av 13 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |